Liquid Biopsy Diagnostic Market 2025 Global Share, Trend, Segmentation and Forecast to 2025

This report, from Stratview Research, studies the global liquid biopsy market over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.

Salient Features of the Report
The Research Report offers an in-depth view of the market, its health and growth, the factors shaping the industry, the competitive dynamics and a glimpse of the future.
The following are the key features of the report:
• Strategic segmentation
• Market analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
• Detailed Competitive Rivalry landscaping
• Market trend and forecast analysis
• Future Growth Boulevards

Get a free sample of the report:
https://www.stratviewresearch.com/Request-Sample/422/liquid-biopsy-diagnostic-market.html

The Liquid Biopsy Diagnostic Market: Highlights
According to a report published by The World Health Organization in 2017, the number of breast cancer deaths around the globe is expected to increase. By 2040, more than 991,000 women are expected to die annually of breast cancer across the globe.

The potential for liquid biopsies to lead to early detection of cancer may impact several product lines, mainly critical illness (CI) and medical insurance. Over the past few years, CI has undergone several innovations. Companies now offer staged, multi-pay, and cancer-only plans. A unique selling point of cancer-only and staged CI plans is they cover early-stage cancers as well. Increased near-term utilization of liquid biopsy as part of routine screening tests or diagnostic protocols could lead to higher cancer incidence rates than anticipated. This could impact the pricing assumptions of certain products, especially those offering early-stage cancer benefits.

Get a TOC of the report:
https://www.stratviewresearch.com/toc/422/liquid-biopsy-diagnostic-market.html

Recent mainstream news flow has made much of the Cancer SEEK diagnostic test, particularly its ability to detect multiple types of cancer from a single blood sample. In reality, further confirmatory tests will be required post-screening before a patient is placed on the current standard of care for their particular cancer. Also, the test’s sensitivity falls to 70% for the purposes of screening certain cancers, which is insufficient to drive standalone clinical decisions. Therefore, considerable further development and validation of liquid biopsy-type platforms are required to establish such a ‘one stop’ diagnostic test. Among the key competitors in liquid biopsy, Biocept, Oncocyte and few others are creating buzz in the market.

Overall, the liquid biopsy (LB) concept complements the personalized medicine approach and provides an innovative way for patient selection in clinical trials, here mutational analysis supports patient eligibility for targeted therapy.

While we do not anticipate that LB will fully replace or directly compete with SB for most diagnostic purposes any time soon, we do very much foresee that LB will complement SB rapidly within the next 3–5 years and will become a tool of choice for dynamic monitoring of patients on treatment or under active surveillance. In many instances, LB will also prompt further imaging workup and/or re-biopsy of tissue lesions.

Comprehensive Market Coverage
Click Here for Other Reports from Stratview Research in the Healthcare & Life Science Industry: https://www.stratviewresearch.com/market-reports/Healthcare-and-Life-Sciences.html

Stratview Research is a global market intelligence firm offering a wide range of services including syndicated market reports, consulting, sourcing intelligence, and customer research. We are a trusted brand in the research industry with capability of commissioning complex projects within a short span of time with high level of accuracy.

Stratview Research
400 Renaissance Center,
Suite 2600,
Detroit, Michigan, MI 48243
United States of America
Phone No. +1-313-307-4176
sales@stratviewresearch.com

This release was published on openPR.